INTRODUCTION: This study evaluated surgical outcomes of infective endocarditis (IE), with particular attention to the impact of intravenous drug use (IVDU). METHODS: Adult patients undergoing surgery for IE between 2011 and 2018 at a single center were included and stratified by IVDU. The primary outcome was overall survival. Secondary outcomes included postoperative complications and hospital readmissions. Kaplan-Meier and multivariable Cox regression were utilized for unadjusted and risk-adjusted survival analyses, respectively. Cumulative incidence function curves were compared for hospital readmissions. RESULTS: A total of 831 patients (mean age 55 years, 34.4% female) were operated on for IE, including 318 (38.3%) with IVDU. Cultures were most commonly positive for streptococcus (25.2%), methicillin-sensitive Staphylococcus aureus (17.7%), enterococcus (14.3%), or methicillin-resistant Staphylococcus aureus (8.4%). The most common procedures included isolated aortic valve repair/replacement (18.8%), aortic root replacement (15.9%), mitral valve repair/replacement (26.7%), aortic and mitral valve replacement (8.4%), and tricuspid valve repair/replacement (7.6%). Mean follow-up was 3.4 ± 2.4 years. Overall 5-year survival was 64% and was similar between IVDU and non-IVDU. Multivariable analysis demonstrated that IVDU was not associated with mortality risk. IVDU patients displayed higher rates of all-cause readmission (61.6% vs 53.9%; P = .03), drug-use readmission (15.4% vs 1.4%; P < .001), and recurrent endocarditis readmission (33.0% vs 13.0%; P < .001). CONCLUSIONS: The majority of patients undergoing surgical treatment of IE are alive at 5-years although readmission rates are high. IVDU is not a risk factor for longitudinal mortality although patients with IVDU are at higher overall readmission risk, driven largely by greater readmissions for drug-use and recurrent endocarditis.
INTRODUCTION: This study evaluated surgical outcomes of infective endocarditis (IE), with particular attention to the impact of intravenous drug use (IVDU). METHODS: Adult patients undergoing surgery for IE between 2011 and 2018 at a single center were included and stratified by IVDU. The primary outcome was overall survival. Secondary outcomes included postoperative complications and hospital readmissions. Kaplan-Meier and multivariable Cox regression were utilized for unadjusted and risk-adjusted survival analyses, respectively. Cumulative incidence function curves were compared for hospital readmissions. RESULTS: A total of 831 patients (mean age 55 years, 34.4% female) were operated on for IE, including 318 (38.3%) with IVDU. Cultures were most commonly positive for streptococcus (25.2%), methicillin-sensitive Staphylococcus aureus (17.7%), enterococcus (14.3%), or methicillin-resistant Staphylococcus aureus (8.4%). The most common procedures included isolated aortic valve repair/replacement (18.8%), aortic root replacement (15.9%), mitral valve repair/replacement (26.7%), aortic and mitral valve replacement (8.4%), and tricuspid valve repair/replacement (7.6%). Mean follow-up was 3.4 ± 2.4 years. Overall 5-year survival was 64% and was similar between IVDU and non-IVDU. Multivariable analysis demonstrated that IVDU was not associated with mortality risk. IVDU patients displayed higher rates of all-cause readmission (61.6% vs 53.9%; P = .03), drug-use readmission (15.4% vs 1.4%; P < .001), and recurrent endocarditis readmission (33.0% vs 13.0%; P < .001). CONCLUSIONS: The majority of patients undergoing surgical treatment of IE are alive at 5-years although readmission rates are high. IVDU is not a risk factor for longitudinal mortality although patients with IVDU are at higher overall readmission risk, driven largely by greater readmissions for drug-use and recurrent endocarditis.
Authors: Gösta B Pettersson; Joseph S Coselli; Gösta B Pettersson; Joseph S Coselli; Syed T Hussain; Brian Griffin; Eugene H Blackstone; Steven M Gordon; Scott A LeMaire; Laila E Woc-Colburn Journal: J Thorac Cardiovasc Surg Date: 2017-01-24 Impact factor: 5.209
Authors: N Fernández-Hidalgo; I Ferreria-González; J R Marsal; A Ribera; M L Aznar; A de Alarcón; E García-Cabrera; J Gálvez-Acebal; G Sánchez-Espín; J M Reguera-Iglesias; J De La Torre-Lima; J M Lomas; C Hidalgo-Tenorio; N Vallejo; B Miranda; A Santos-Ortega; M A Castro; P Tornos; D García-Dorado; B Almirante Journal: Clin Microbiol Infect Date: 2018-03-03 Impact factor: 8.067
Authors: Ryan Hall; Michael Shaughnessy; Griffin Boll; Kenneth Warner; Helen W Boucher; Raveendhara R Bannuru; Alysse G Wurcel Journal: Clin Infect Dis Date: 2019-09-13 Impact factor: 9.079
Authors: P Alexander Leahey; Mary T LaSalvia; Elana S Rosenthal; Adolf W Karchmer; Christopher F Rowley Journal: Open Forum Infect Dis Date: 2019-03-01 Impact factor: 3.835
Authors: Sang Myung Han; Robert A Sorabella; Sowmya Vasan; Mark Grbic; Daniel Lambert; Rahul Prasad; Catherine Wang; Paul Kurlansky; Michael A Borger; Rachel Gordon; Isaac George Journal: J Cardiothorac Surg Date: 2017-07-20 Impact factor: 1.637
Authors: Julia Grapsa; Christopher Blauth; Y S Chandrashekhar; Bernard Prendergast; Blair Erb; Michael Mack; Valentin Fuster Journal: JACC Case Rep Date: 2021-11-15